

Brineura® (cerliponase alfa) **Medication Precertification Request**

Page 1 of 1

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY:<u>711</u>)

1-888-267-3277

For Medicare Advantage Part B:

Please Use Medicare Request Form

Please indicate: Start of tr	reatment: Start datetion of therapy: Date of last		1		
Precertification Requested By		ueaunent	 Phone:	Fax	C
A. PATIENT INFORMATION					
First Name:		Last Name:			
Address:		City:		State:	ZIP:
Home Phone:	Work	Phone:		Cell Phone:	
T	Allergies:			E-mail:	
Current Weight: lbs		Hoight:	inches or		
<u> </u>		rieignt.	IIICHES OF	_ (1118	
B. INSURANCE INFORMATION					
Aetna Member ID #:		Does patient have other coverage?			
Insured:		Insured:			
Medicare: Yes No If yes, provide ID #: Medicaid: Yes No If yes, provide ID #: Medicaid: Yes No If yes, provide ID #:					
C. PRESCRIBER INFORMAT First Name:	ION	Last Name:		(Chack One): MIN).
Address:				State:	ZIP:
T	Fax:	City: St Lic #:	NPI #:	DEA #:	UPIN:
	гах.	Office Contact Name:	INPI #.		UPIN.
Provider E-mail:	tabolic Specialist			Phone:	
Specialty (Check one):					
☐ Outpatient Infusion Center Center Name: ☐ Home Infusion Center Agency Name: ☐ Administration code(s) (CP Address:	Phone:		Dispensing Provider/P	☐ Retail Pharm	c:
E. OUTPATIENT INFUSION TREATMENT Requesting Outpatient Infusion Treatment? Yes No If Yes, CPT Code: \$9357 96305 96366 Other					
F. PRODUCT INFORMATION					
Request is for: Brineura (cerl	iponase alfa) Dose:	F	requency:		
G. DIAGNOSIS INFORMATIO	N – Please indicate primary	/ ICD code and specify	any other where applica	able.	
Primary ICD Code:	Secon	ary ICD Code: Other ICD Code:			
H. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.					
For All Requests (clinical documentation required for all requests): Yes No Is the patient diagnosed with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) (also known as tripeptidyl peptidase 1 (TPP1) deficiency)? Yes No Does the patient have intraventricular access device-related complications (e.g., leakage, device failure, device-related infection) or a ventriculoperitoneal shunt?					
☐ Yes ☐ No Will the requested medication be administered by, or under the direction of a physician knowledgeable in intraventricular administration?					
For Initiation Requests (clinical documentation required for all requests): Yes No Was the diagnosis confirmed by either an enzyme assay demonstrating a deficiency of tripeptidyl peptidase 1 (TPP1) enzyme activity OR by genetic testing?					
For Continuation Requests (clinical documentation required for all requests):					
☐ Yes ☐ No Has the patient experienced no loss of ambulation or a slowed loss of ambulation from baseline?					
→ Please indicate ambulation status: ☐ No loss of ambulation ☐ Slowed loss of ambulation					
H. ACKNOWLEDGEMENT					
Request Completed By (Signature)	gnature Required):			Da	ate: ///
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits					

The plan may request additional information or clarification, if needed, to evaluate requests.

a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.